Livia Leuzzi

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.

V. Mazzaferro, F. D. De Braud, M. Milione, 2015, Future oncology.

Update on medical treatment of small intestinal neuroendocrine tumors

M. Milione, G. Lo Russo, M. Maccauro, 2016, Expert review of anticancer therapy.

Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors

F. D. De Braud, S. Pusceddu, R. Buzzoni, 2014, Tumori.

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

B. Di Camillo, A. Frustaci, M. Deodato, 2021, Cancers.

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.

V. Mazzaferro, S. Marceglia, M. Milione, 2016, Future oncology.

A novel start‐loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms

R. Cairoli, A. Beghini, Livia Leuzzi, 2022, Hematological oncology.

Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

P. Pasini, I. Naldi, S. Paolini, 2023, American journal of hematology.